- Home
- JKS vs OCS Comparison
JKS vs OCS Comparison
Compare JKS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKS | OCS |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | JKS | OCS |
|---|---|---|
| Price | $23.51 | $24.73 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $22.33 | ★ $41.86 |
| AVG Volume (30 Days) | ★ 421.1K | 372.9K |
| Earning Date | 04-28-2026 | 03-03-2026 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $466.06 |
| Revenue Next Year | $37.42 | $502.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.42 | $14.00 |
| 52 Week High | $31.88 | $30.68 |
Technical Indicators
Market Signals| Indicator | JKS | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 36.89 |
| Support Level | $21.38 | $19.00 |
| Resistance Level | $23.76 | $29.19 |
| Average True Range (ATR) | 0.90 | 1.33 |
| MACD | -0.10 | -0.41 |
| Stochastic Oscillator | 15.22 | 2.43 |
Price Performance
Historical ComparisonAbout JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.